Biotherapeutics News: Breaking Biotherapeutics News, Comments and Articles. - Page: 2

[ThromboGenics] teams up with [Eleven Biotherapeutics] for back-of-the-eye disease treatment

Three-year-old protein-based therapeutics developer [Eleven Biotherapeutics] has agreed to use its {AMP-Rx} protein design technology to optimize one of [ThromboGenics NV]’s therapeutics. The biologic will be used to treat back-of-the-eye diseases,...

BioTime, Inc. Closes on $9 Million Financing

BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it announced on June 3, 2013 and received gross proceeds of $9,057,966. BioTime intends to use the net proceeds from the sale of its common shares and warrants for working capital and other general corporate purposes, and may invest a portion of the proceeds in...

Alnylam to Webcast Presentation at Goldman Sachs 34th Annual Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Goldman Sachs 34th Annual Global Healthcare Conference on Thursday, June 13, 2013 at 10:40 a.m. PT (1:40 p.m. ET) at the Terranea Resort in Rancho Palos Verdes, Calif. A live audio webcast...

Circulation 62% More Likely to Return with ZOLL AutoPulse

Clinical Benefits Unmatched by Other Mechanical CPR Systems ZOLL® Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that a paper just published in Critical Care Medicine reported the likelihood of achieving a return of spontaneous circulation (ROSC) after sudden cardiac arrest (SCA) is 62% gr...

Wound Management Market 2019 Forecasts & Research Reports

DALLAS, June 6, 2013 /PRNewswire-iReach/ -- ReportsnReports.com offers new market research reports on advanced wound management with forecasts to 2016 & 2019, wound treatment products market in China as well as H1 2013 pipeline review on therapeutic developments for wounds. (Photo: http://photos.prnewswire.com/prnh/20130606/CG27603) Advanced Wound Management Market to 2019 –...

NW Bio's Dr. Marnix Bosch To Present At Brain Tumor Biotech Summit In New York

BETHESDA, Md., June 6, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, today announced that its Chief Technical Officer, Dr. Marnix Bosch, will make a presentation at the Brain Tumor Biotech Summit sponsored by the Weill Cornell Medical College and Voices Against...

Acceleron Named to the “Best Places to Work” List by The Scientist Magazine

Acceleron recognized among survey of more than 200 companies Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced that it was named to the 2013 “Best Places to Work in Industry” by The Scientist magazine in their 11th annual survey. The survey included responses from 240...

SAFC Strengthens Biopharmaceutical Market Presence in Asia with Commercial Licensing of CHOZN® Cell Line Bioproduction Platform

ST LOUIS, June 4, 2013 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that SAFC® Commercial (www.safcglobal.com), its custom manufacturing services business unit, has won commercial sales and licensing contracts with two leading Asian biopharmaceutical companies for the purchase of CHOZN®, their off-the-shelf cell line production platform. The contracts fea...

Flexicon machine aids biotherapeutics development work at Cancer Research UK

A Flexicon FP50 tabletop filling and stoppering machine from Watson-Marlow Pumps Group has automated a previously manual process at a Cancer Research UK facility in Hertfordshire. The FP50 is delivering increased speed and reliability into this critical operation, as well as enhanced vial filling accuracy. The Cancer Research UK Biotherapeutics Development Unit (BDU) was constructed in 2010 at So...

Scientists work together to optimize the quality, availability of fecal microbiota transplants

Monarch Labs and the BioTherapeutics, Education & Research Foundation announced today their collaboration to develop two fecal microbiota transplantation products.

Monarch Labs and BTER Foundation collaborate to develop fecal transplantion products

(Monarch Labs) Monarch Labs intends to supply two fecal microbiota transplantation (FMT) products: A processing and banking service for autologous FMT transplantation, and a GMP controlled FMT product for allograft transplantation, called Medical Mic...

ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein

THOUSAND OAKS, Calif., June 3, 2013 /PRNewswire/ -- ImmunGene, Inc. today announced that pre‑clinical studies of its novel anti‑CD20 antibody-interferon alpha fusion protein, IGN002, demonstrated superior anti‑lymphoma activity against numerous cell lines in vitro and against established human xenograft tumors grown in mice. The findings were presented in the Developmental Therap...

BioTime, Inc. to Raise $9 Million in Registered Direct Offering

BioTime, Inc. (NYSE MKT: BTX) today announced that it has agreed to sell up to an aggregate of 2,180,016 common shares and 545,004 warrants to purchase common shares, in “units” with each unit consisting of one common share and one-quarter of a warrant, at an offering price of $4.155 per unit. BioTime expects to receive gross proceeds of $9,057,966.48...

NW Bio Added To The MSCI Global MicroCap Index

BETHESDA, Md., June 3, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that NW Bio was added to the MSCI Global MicroCap Index as of the close of the stock market on Friday, May 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084L...

Green Innovations and Tauriga Sciences, Inc. execute Exclusive North American Licensing Agreement for the Commercialization of Hospital Grade Products including 100% Tree-Free Bamboo-Based Disinfectant Wipes

CAPE CORAL, Fla., June 3, 2013 /PRNewswire/ -- Green Innovations Ltd. (OTCQB: GNIN) (OTCBB: GNIN) ("Green Innovations" or the "Company") is pleased to announce that on May 31, 2013, its wholly-owned subsidiary, Green Hygienics, Inc. ("Green Hygienics"), executed an exclusive North American licensing agreement with Tauriga Sciences Inc. (OTCQB: TAUG) ("Tauriga") (the "Licensing Agreement"...

SmithOnStocks Opines Week Of June 2, 2013

By Smith On Stocks: Overview of This Week's Report This week I published a major report on Alimera Sciences (ALIM) and pSivida (PSDV) which led to my recommendation of pSivida. I also comment on Neuralstem's (CUR) press release on a rat study modeling the use of NSI-566 neural stem cells in an acute spinal cord injury which showed some encouraging data. The lead investigator of the Neuralstem P...

Eleven Biotherapeutics, ThromboGenics deal

Caliber Biotherapeutics, ImmunGene, The Leukemia and Lymphoma Society cancer news

BioProcess International May 2013 Issue Published on the App Store Featuring App-only Exclusive Content

Exclusive content includes articles, interviews and audio files featuring authors and BioProcess International editors. New York, NY (PRWEB) May 31, 2013 BioProcess International (BPI) announces the publication of the May 2013 issue of BioProcess International on the App Store for iPad and iPhone. With this issue, BioProcess International continues to bring exclusive app-only content available o...

Alethia signs research deal with IBC Generium for EMT inhibitor

Alethia Biotherapeutics has signed a licensing and research agreement with the International Biotechnology Center (IBC) Generium to develop monoclonal antibodies (mAb)inhibitor of epithelial-to-mesenchymal transition (EMT), AB-16B5.

Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City

SAN DIEGO, May 30, 2013 /PRNewswire/ -- Sorrento Therapeutics (OTCBB: SRNE; or STI) today announced that Henry Ji, Ph.D., the Company's President and Chief Executive Officer, will present at the Jefferies 2013 Global Healthcare Conference on Thursday, June 6th, 2013, at 3:00 PM ET. The conference will be held at the Grand Hyatt in New York, NY. A live webcast of the presentation will be ava...

Cancer Research UK installs Flexicon FP50

Delivers increased speed and reliability into the filling and stoppering process at the Cancer Research UK Biotherapeutics Development Unit (BDU)

LLS, Valor Biotherapeutics partner to advance novel therapy

The Leukemia & Lymphoma Society (LLS), a global voluntary health agency,  is committing approximately $6 million to Valor Biotherapeutics, a joint venture of biotechnology companies ImmunGene and Caliber, to co-fund the completion of preclinical dev...

ThromboGenics licenses technology from Eleven Biotherapeutics to develop eye diseases treatments

ThromboGenics NV, a biopharmaceutical company focused on developing and commercialising innovative ophthalmic medicines, has commenced research and development of innovative protein therapeutics to address a novel biologic target identified by the co...

QPS Holdings LLC and Hepregen Corporation Announce HepatoPac™ Commercial Partnership

Agreement Provides for Co-Promotion, Marketing and Sales of Services Utilizing Hepregen’s Proprietary HepatoPac™ Products for Drug Metabolism and Pharmacokinetic Applications QPS Holdings, LLC, a US-headquartered contract research organization (“CRO”), and Hepregen Corporation, developer of HepatoPacTM and HepatoMuneTM “liver-in-a-dish” pro...